

学术搜索

找到约 6,090 条结果 (用时0.10秒)

文章

我的图书馆

时间不限

2015以来

2014以来

2011以来

自定义范围...

按相关性排序

按日期排序

搜索所有网页

中文网页

英语网页

☒ 包括专利☒ 包含引用☐ 创建快讯

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

B Escudier, J Bellmunt, S Négrier... - Journal of Clinical ..., 2010 - jco.ascopubs.org

... Over the last 4 years, the US Food and Drug Administration (FDA) and the European Medicines ... over to receive bevacizumab before progression; censoring these patients impacted on the final OS results. ... As a marker of efficacy, PFS may be adopted as a primary end point to ...

被引用次数: 510 相关文章 所有 6 个版本 引用 保存

ascopubs.org 中的 [HTML]

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

F Di Nicolantonio, M Martini, F Molinari... - Journal of Clinical ..., 2008 - jco.ascopubs.org

... The objective tumor response was the end point of our exploratory study. ... Final approval of manuscript: Federica Di Nicolantonio, Miriam Martini, Francesca Molinari, Andrea Sartore-Bianchi, Piercarlo ... 19:711-716, 2008) phase II trial (12 patients) and as third-line treatment in the ...

被引用次数: 1219 相关文章 所有 10 个版本 引用 保存

ascopubs.org 中的 [HTML]

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

B Escudier, A Pluzanska, P Koralewski, A Ravaud... - The Lancet, 2008 - Elsevier

... The final analysis of progression-free survival is reported here. ... The aim of this study was to determine whether first-line bevacizumab plus interferon improves efficacy compared with ... Patients without an event were censored on the day of last follow-up assessment or the day of ...

被引用次数: 1801 相关文章 所有 18 个版本 引用 保存

ubc.ca 中的 [PDF]

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

M Scartozzi, E Galizia, S Chiorrini... - Annals of ..., 2009 - Eur Soc Med Oncology

... of bevacizumab, at half infusion, immediately after and after 1 h from the end of bevacizumab ... between the start of bevacizumab therapy to clinical progression or death or last follow-up ... Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus ...

被引用次数: 245 相关文章 所有 11 个版本 引用 保存

oxfordjournals.org 中的 [HTML]

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

A Bardelli, S Siena - Journal of Clinical Oncology, 2010 - jco.ascopubs.org

... in KRAS/BRAF wild-type tumors are transient, and even in the best cases, they do not last for longer ... Final approval of manuscript: Alberto Bardelli, Salvatore Siena. ... Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article. ...

ascopubs.org 中的 [HTML]

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 21610

Manuscript Type: Retrospective Study

Last line therapy with sorafenib in colorectal cancer: A retrospective analysis

Martchenko K *et al.* Sorafenib in colorectal cancer

Ksenia Martchenko, Irene Schmidtman, Thomas Thomaids, Verena Thole, Peter R Galle, Marc Becker, Markus Möhler, Thomas C Wehler, Carl C Schimanski

Ksenia Martchenko, Carl C Schimanski, Department of Internal Medicine, Marienhospital, 64285 Darmstadt, Germany

Irene Schmidtman, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), Johannes Gutenberg University Hospital of Mainz, 55131 Mainz, Germany

Thomas Thomaids, Peter R Galle, Markus Möhler, Carl C Schimanski, First

Match Overview

1	CrossCheck 249 words Wehler, Thomas C., Swaantje Hamdi, Annett Maderer, Claudine Graf, Ines Gockel, Irene Schmidtman, Michael Hainz,	6%
2	Internet 96 words crawled on 14-Dec-2015 www.wjgnet.com	2%
3	CrossCheck 24 words Fujii, Hideki. "Comparison of peg-interferon, ribavirin plus ... elaprevir vs simeprevir by propensity score matching", Worl	1%

学术搜索

找到约 6,650 条结果 (用时0.03秒)

文章

我的图书馆

时间不限

2016以来

2015以来

2012以来

自定义范围...

按相关性排序

按日期排序

搜索所有网页

中文网页

简体中文网页

☒ 包括专利

☒ 包含引用

创建快讯

小提示: 只搜索**中文(简体)**结果, 可在 [学术搜索设置](#) 指定搜索语言

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): **final analysis** of overall survival

B Escudier, J Bellmunt, S Négrier... - Journal of Clinical ..., 2010 - jco.ascopubs.org

... Over the **last** 4 years, the US Food and Drug Administration (FDA) and the European Medicines ... over to receive bevacizumab before progression; censoring these patients impacted on the **final** OS results. ... As a marker of efficacy, PFS may be adopted as a primary **end** point to ...

被引用次数: 545 相关文章 所有 6 个版本 引用 保存

ascopubs.org 中的 [HTML]

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic **colorectal cancer**

F Di Nicolantonio, M Martini, F Molinari... - Journal of Clinical ..., 2008 - jco.ascopubs.org

... The objective **tumor** response was the **end** point of our exploratory study. ... **Final** approval of manuscript: Federica Di Nicolantonio, Miriam Martini, Francesca Molinari, Andrea Sartore-Bianchi, Piercarlo ... 19:711-716, 2008) phase II trial (12 patients) and as third-line **treatment** in the ...

被引用次数: 1280 相关文章 所有 10 个版本 引用 保存

ascopubs.org 中的 [HTML]

Bevacizumab plus interferon alfa-2a for **treatment** of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

B Escudier, A Pluzanska, P Koralewski, A Ravaud... - The Lancet, 2008 - Elsevier

... The **final analysis** of progression-free survival is reported here. ... The aim of this study was to determine whether first-line bevacizumab plus interferon improves efficacy compared with ... Patients without an event were censored on the day of **last** follow-up assessment or the day of ...

被引用次数: 1871 相关文章 所有 18 个版本 引用 保存

ubc.ca 中的 [PDF]

Arterial hypertension correlates with clinical outcome in **colorectal cancer** patients treated with first-line bevacizumab

M Scartozzi, E Galizia, S Chiellini... - Annals of ..., 2009 - Eur Soc Med Oncology

... of bevacizumab, at half infusion, immediately after and after 1 h from the **end** of bevacizumab ... between the start of bevacizumab **therapy** to clinical progression or death or **last** follow-up ... **Final analysis** of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus ...

被引用次数: 258 相关文章 所有 11 个版本 引用 保存

oxfordjournals.org 中的 [HTML]

Molecular mechanisms of resistance to cetuximab and panitumumab in **colorectal cancer**

ascopubs.org 中的 [HTML]

[全部](#) [图片](#) [新闻](#) [视频](#) [更多 ▾](#) [搜索工具](#)

找到约 76,200 条结果 (用时 0.63 秒)

Google 学术 : Last line therapy with sorafenib in colorectal cancer: A retrospective analysis

... renal cell carcinoma (AVOREN): final analysis of ... - Escudier - 被引用次数 : 545

... or cetuximab in metastatic colorectal cancer - Di Nicolantonio - 被引用次数 : 1283

... plus interferon alfa-2a for treatment of metastatic renal ... - Escudier - 被引用次数 : 1874

Colorectal Cancer | 2013 ASCO Annual Meeting | Abstracts ...

[meetinglibrary.asco.org](#) > ... > 2013 ASCO Annual Meeting ▾ [翻译此页](#)

FOLFIRI plus bevacizumab (bev) as second-line therapy in patients (pts) with metastatic ... Prospective analysis of UGT1A1 genotyping for predicting toxicities in ... with resected stage II-III rectal cancer: Final analysis of R98 intergroup study. with sorafenib (S) versus placebo (P) in second-line metastatic colorectal ...

A phase I study of sorafenib with FOLFIRI as first-line ...

[meetinglibrary.asco.org](#) > ... > 2013 ASCO Annual Meeting ▾ [翻译此页](#)

... of sorafenib with FOLFIRI as first-line therapy for metastatic colorectal cancer (mCRC): ... for metastatic colorectal cancer in Canada: A retrospective analysis.

Treating hepatocellular carcinoma progression following ...

[www.ncbi.nlm.nih.gov](#) > ... > PubMed Central (PMC) ▾ [翻译此页](#)

作者 : AR He - 2013 - 被引用次数 : 9 - 相关文章

Treating hepatocellular carcinoma progression following first-line sorafenib: ... Over the last 5 years, molecularly targeted therapy has become a mainstay in the ... in a small retrospective analysis of 53 patients treated with sorafenib for HCC, ... found that patients with metastatic colorectal cancer (mCRC) who remained on ...